Your trusted source for investing success

Tag: overdose

Intellipharmaceutics Announces 2016 Year End Results

TORONTO, Feb. 10, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2016. 

Intellipharmaceutics Submits New Drug Application for Rexista®

Intellipharmaceutics International, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has filed a New Drug Application seeking authorization to market its Rexista.

Intellipharmaceutics Announces Third Quarter 2016 Results

Intellipharmaceutics International, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2016.

Insys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using Pharmaceutical Cannabidiol

PHOENIX, Aug. 18, 2016 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad,

Opiant Pharmaceuticals, Inc.’s Partner, Adapt Pharma Limited, Submits New Drug Submission for Naloxone Nasal Spray to Health Canada

SANTA MONICA, Calif., May 06, 2016 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced that its commercial partner for naloxone nasal spray for the emergency reversal of opioid overdose, Adapt Pharma Limited (“Adapt”), has submitted

FDA Issues Complete Response Letter for Digital Medicine New Drug Application

TOKYO & REDWOOD CITY, Calif.–(BUSINESS WIRE)–Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health
(Proteus) today announced that the United States Food and Drug
Administration (FDA) has issued a Complete Response Letter (CRL) for
their Digital Medicine, a drug/device combination product, which
combines Otsuka’s ABILIFY® (aripiprazole), an atypical antipsychotic,
with the FDA-cleared Proteus ingestible sensor

RespireRx Pharmaceuticals Inc., the University of Alberta and the University of Florida Provide Update on Collaborative Research Activities

Use of Ampakines as a Novel Therapy for Overcoming Central Respiratory Depression

GLEN ROCK, NJ–(Marketwired – Apr 1, 2016) – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, is providing an update on

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network